Alaunos Therapeutics (TCRT) Total Non-Current Liabilities (2009 - 2023)

Alaunos Therapeutics has reported Total Non-Current Liabilities for 13 years, with the latest figure at $2.0 million in Q4 2023.

• For the quarter ending Q4 2023, Total Non-Current Liabilities fell 92.58% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2023 stood at $2.0 million (down 92.58% YoY), and the FY2023 full-year result was $2.0 million, down 92.58% from the prior year.
• Total Non-Current Liabilities for Q4 2023 stood at $2.0 million, down from $5.5 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $36.8 million in Q4 2021, with the low at $2.0 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $20.6 million across 3 years, with a median of $22.7 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities dropped 28.4% — and 2023, when it sank 92.58%.
• Alaunos Therapeutics' Total Non-Current Liabilities stood at $36.8 million in 2021, then retreated by 28.4% to $26.4 million in 2022, then slumped by 92.58% to $2.0 million in 2023.
• The last three Total Non-Current Liabilities figures came in at $2.0 million (Q4 2023), $5.5 million (Q3 2023), and $6.3 million (Q2 2023), per Business Quant data.